Table 2.
Summary of ongoing studies combining radiation and immunotherapy in metastatic NSCLC.
| Phase | Patients | Treatment | Primary outcome | |
|---|---|---|---|---|
| NCT03158883 [67] | I | 8 | Avelumab + SBRT 50 Gy/5 fx | ORR |
| NCT03224871 [68] | I | 3 | Nivolumab + pembrolizumab + intratumor IL-2 + SBRT 24 Gy/3 fx | MTD |
| NCT03436056 (PRIMING) [69] | I | 2 | Pembrolizumab + SBRT 30 Gy/3 fx or 54 Gy/3 fx | MTD |
| NCT03812549 [70] | I | 29 | Sintilimab + SBRT 30 Gy/3 fx + low dose RT 2 Gy/1 fx or 4 Gy/2 fx or 10 Gy/5 fx | MTD |
| NCT03223155 (COSINR) [71] | I | 80 | Ipilimumab + nivolumab + SBRT 3-5 fx, 2-4 sites | MTD |
| NCT02639026 [72] | I | 30 | Durvalumab + tremelimumab + SBRT 24 Gy/3fx or 17 Gy/1 fx | MTD |
| NCT03275597 [73] | I | 17 | Durvalumab + tremelimumab + SBRT 30-50 Gy/5 fx | MTD |
| NCT02444741 [37] | I/II | 104 | Pembrolizumab + SBRT 4 fx or HFRT 15 fx | MTD, ORR |
| NCT02239900 [38] | I/II | 143 | Ipilimumab + SBRT 50 Gy/4 fx or HFRT 60 Gy/10 fx | MTD |
| NCT03168464 [74] | I/II | 15 | Ipilimumab + nivolumab + SBRT 30 Gy/5 fx | ORR |
| NCT02221739 [75] | I/II | 39 | Ipilimumab + SBRT 30 Gy/5 fx | ORR |
| NCT03176173 (RRADICAL) [76] | II | 44 | Nivolumab + pembrolizumab + atezolizumab + SBRT or HFRT 1-10 fx | PFS |
| NCT03965468 (CHESS) [77] | II | 48 | Durvalumab + chemotherapy + SBRT or HFRT 1-10 fx | PFS |
| NCT03044626 (FORCE) [78] | II | 101 | Nivolumab + RT 20 Gy/5 fx | ORR |
| NCT02658097 [79] | II | 13 | Pembrolizumab + RT 8 Gy/1 fx | ORR |
| NCT04929041 (Alliance A082002) [25] | II/III | 100 | Nivolumab ± chemotherapy ± SBRT | PFS, OS |
| NCT03391869, (LONESTAR) [80] | III | 360 | Ipilimumab + nivolumab ± SBRT | OS |
| NCT03867175 [81] | III | 112 | Pembrolizumab ± SBRT or HFRT 3-10 fx | PFS |
| NCT03774732 (NIRVANA-LUNG) [82] | III | 460 | Pembrolizumab + chemotherapy ± SBRT 81 Gy/3 fx | OS |
SBRT=stereotactic body radiation therapy, HFRT=hypofractionated RT, ORR=overall response rate, MTD=maximum tolerated dose, PFS=progression free survival, OS=overall survival